IOL Chemicals & Pharmaceuticals Ltd (IOLCP) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management announced a significant INR 500 crore capex plan for growth projects, including Ibuprofen expansion and new CDMO/CMO facilities, to be fully funded by internal accruals.
- The company upgraded its full-year FY27 guidance to over 25% revenue growth, surpassing its earlier target of INR 2,700 crore, with an expected EBITDA margin of 14-15%.
- A new specialty chemical plant will operate on a cost-plus CMO model for a global client, marking a strategic entry into the chemical contract manufacturing business with high visibility.
Performance Overview
- The company maintained positive momentum during the second quarter of FY27, delivering healthy growth across businesses with a meaningful improvement in profitability.
- Performance was strong despite geopolitical uncertainties, global supply chain disruptions, and volatility in raw material prices, attributed to a focus on product mix and operational efficiencies.
- Significant regulatory milestones were achieved, including a Certificate of Suitability (CEP) for Fenofibrate Process II, GMP certification for the formulation CDMO facility, and EU REACH registration for Triacetin.
- Announced three major manufacturing projects with a combined investment of approximately INR 500 crore, funded through internal accruals.
- The non-Ibuprofen pharmaceutical portfolio registered strong growth, contributing 45% of pharmaceutical revenue, up from 38% in the prior year's quarter.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.